Yale Cancer Center Precision Medicine Tumor Board: molecular findings alter a diagnosis and treatment plan

Lancet Oncol. 2021 Mar;22(3):306-307. doi: 10.1016/S1470-2045(20)30683-5.

Authors

Joanna A Gibson¹, Karin E Finberg¹, ILKe Nalbantoglu¹, Michael Cecchini², Amanda Ganzak³, Zenta Walther¹, Jeffrey L Sklar¹, Joseph P Eder², Sarah B Goldberg⁴

Affiliations

¹ Department of Pathology, Yale School of Medicine, New Haven, CT 06510, USA.
² Department of Medicine, Medical Oncology, Yale School of Medicine, New Haven, CT 06510, USA.
³ Smilow Cancer Genetics and Prevention Program, Yale Cancer Center, New Haven, CT, USA.
⁴ Department of Medicine, Medical Oncology, Yale School of Medicine, New Haven, CT 06510, USA. Electronic address: sarah.goldberg@yale.edu.

PMID: 33662283
DOI: 10.1016/S1470-2045(20)30683-5

No abstract available

Publication types

Case Reports

MeSH terms

Adenocarcinoma / diagnosis
Adenocarcinoma / genetics
Adenocarcinoma / therapy*
Biomarkers, Tumor / genetics*
Diagnosis, Differential
Gallbladder Neoplasms / diagnosis
Gallbladder Neoplasms / genetics
Gallbladder Neoplasms / therapy*
High-Throughput Nucleotide Sequencing
Humans
Male
Mesothelioma / diagnosis
Mesothelioma / genetics
Mesothelioma / therapy*
Middle Aged
Molecular Targeted Therapy
Mutation
Patient Care Planning*
Peritoneal Neoplasms / diagnosis
Peritoneal Neoplasms / genetics
Peritoneal Neoplasms / therapy*
Precision Medicine*
Prognosis

Substances

Biomarkers, Tumor